Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

This study is examining the real-world effectiveness of combining immune checkpoint therapy (anti-PD-1 or anti-PD-L1 drugs) with drugs that cut off blood supply to tumors (anti-angiogenic agents) as a first-line treatment for advanced liver cancer (hepatocellular carcinoma or HCC) that cannot be surgically removed. **You may be eligible if...** - You have locally advanced or metastatic unresectable hepatocellular carcinoma (HCC) - You have not previously received systemic (body-wide) treatment for HCC - Your cancer is classified as BCLC Stage B or C - You have at least one measurable lesion - Your liver function is relatively preserved (Child-Pugh class A5–B7) - You are in good general health (ECOG 0–1) **You may NOT be eligible if...** - You have a mixed type of liver cancer (e.g., cholangiocarcinoma component) - You have had prior immunotherapy or anti-angiogenic treatment - You have uncontrolled hepatitis B or C - You have serious heart, kidney, or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.